India Will Miss Investment Boat If New IPR Policy Just All Talk
Executive Summary
India’s more muscular intellectual property protection policy is a good first step but the government will have to “walk the talk” to attract significant new investment from global pharmaceutical companies, say US experts. Implementation of the policy will be the key measure of its success, they say.
You may also be interested in...
India Upholds Prevnar 13 Patent In Big Win For Pfizer
India has awarded Pfizer a patent for its blockbuster pneumonia vaccine Prevnar13, handing the pharmaceutical giant a big victory in a case which has been closely watched as a key test of the country’s patentability criteria.
Rx Pricing Practices Of US Trading Partners Criticized By Trade Office
US Trade Representative also highlights restrictive patentability criteria in Canada, India and Indonesia in its annual Special 301 report.
India Liberalizes Foreign Investments But Will Money Flow?
Following the easing of India’s foreign direct investment norms in the pharmaceutical sector, reforms are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.